Skip to main content

Table 3 The incidence of intraoperative adverse events in both groups

From: Comparison of the efficacy and safety of sedation protocols with the use of dexmedetomidine–remifentanil and propofol–remifentanil during percutaneous closure of atrial septal defects: a randomized clinical trial

 

D–R group (n = 29)

P–R group (n = 30)

difference (95% CI)

P value

Respiratory adverse events, n (%)

1 (3.4%)

8 (26.7%)

23.3% (6.2 to 40.5%)

0.026

Cardiovascular adverse events, n (%)

6 (20.7%)

4 (13.3%)

7.4% (− 11.7 to 26.5%)

0.506

Hypertension, n (%)

2 (6.9%)

0 (0%)

6.9% (− 2.3 to 16.1%)

0.237

Hypotension, n (%)

2 (6.9%)

3 (10%)

3.1% (− 11.1 to 17.3%)

1.000

Bradycardia, n (%)

2 (6.9%)

1 (3.3%)

3.6% (− 7.6 to 14.8%)

0.612

  1. D–R group: dexmedetomidine–remifentanil group; P–R group: propofol–remifentanil group